Eustachian Tuboplasty as an Adjunct Treatment to Concurrent Tympanostomy Tube Insertion for Otitis Media With Effusion: A Systematic Review Authors: Hunter Geneau, Hailey C Lewis, Sean P Holmes Published: 2026 ABSTRACT ABSTRACTObjectivesChronic otitis media with effusion (COME) is defined as an accumulation of nonpurulent fluid within the middle ear space without evidence of an acute infection. A primary factor in the development of COME is eustachian tube dysfunction. Tympanostomy tube insertion (TTI) has long been an established and effective means of treating OME; eustachian tuboplasty (ET) has emerged as another treatment measure. There are limited studies that combine TTI with ET and compare the effectiveness of combined treatments to TTI alone. The focus of this systematic review is to assess if the adjunctive treatment of ET with TTI is superior to TTI.MethodsA study question was identified, and inclusion and exclusion criteria were generated. Search criteria were defined by two independent reviewers working in parallel, and PubMed/MEDLINE, Embase, Scopus, and Cochrane/CENTRAL databases were searched to assess possible studies. Ultimately, four cohort studies were used in data analysis. Outcome data was extracted and pooled whenever possible across the studies to generate a meta‐analysis and narrative synthesis.ResultsA total of 294 ears were assessed and primary outcome data of ETDQ‐7, Air‐Bone‐Gap Reduction, and symptom recurrence were assessed using pooled mean difference and pooled risk reduction comparing between the ET + TTI and TTI groups. All outcomes appeared to favor ET + TTI; however, heterogeneity was present between the studies. The ET + TTI group had an average recurrence of symptoms at 9.9% and the TTI group had an average recurrence of symptoms at 24.9% (p = 0.02).DiscussionThis analysis suggests there is a clinically significant reduction in recurrence of symptoms when ET is added to TTI as an adjunctive treatment for OME in adults. Additional studies with adequate control groups need to be conducted to be able to confidently state that concurrent ET with TTI is better than TTI alone.Keywords: balloon dilation, eustachian tuboplasty, radiofrequency ablation, tympanostomy tube insertion Introduction Chronic otitis media with effusion (COME) is defined as an accumulation of nonpurulent fluid, which can be mucoid or serous, within the middle ear space without evidence of an acute infection [1]. Despite its prevalence treatment and management remain complex and difficult, with many interventions, both medical and surgical. These patients can experience an array of symptoms, ranging from asymptomatic presentation to ear fullness and hearing loss. As fluid collects and presses on the tympanic membrane, pressure builds, impeding proper vibration causing hearing impairment. Additionally, this can increase the risk of infection and other middle ear problems [1]. Otitis media with effusion (OME) becomes chronic when the effusion or symptoms last for at least 3 months [1]. Several factors have been proposed as possible contributing factors to OME, particularly host characteristics, like physiological dysfunction of the eustachian tube. The eustachian tube is essential for balancing air pressure between the middle ear and the outside environment. It also allows for proper drainage of secretions and effusions from the middle ear space [1]. The eustachian tube itself is a fibrocartilaginous structure that is complex, consisting of mucosa, cartilage, soft tissues and peritubal muscles [2]. The eustachian tube primarily has three functions: protection from nasopharyngeal sound pressures, clearance of middle ear secretions and ventilation of middle ear space [3]. It has been proposed that the fibrocartilaginous section's primary purpose is in the optimization of middle ear function through its pressure maintenance function, allowing for proper balance with the outside environment [2]. This function is created via intermittent brief tubal dilation which typically occurs with swallowing or yawning [2]. The primary tubal dysfunction that leads to otitis media is obstruction, abnormal patency, or some combination of both [3]. If ventilation does not occur and the dysfunction persists, this can result in otitis media with effusion [3]. Intrinsic mechanical obstruction of the eustachian tube is primarily due to inflammation of the mucosa. For example, upper respiratory infections in children have been shown to temporarily significantly decrease eustachian tube function due to inflammation. Allergies function in a similar way leading to swelling of the mucosa [3]. In terms of diagnosing OME, audiometry and tympanometry are generally considered to be the most effective diagnostic tools [1]. Classically, patients with OME experience normal to moderate hearing loss and typically present with a flat, Type B tympanogram [4]. A particular concern is conductive hearing loss. In children with effusion, a study found up to 15% have hearing loss with OME, and of those, 88.9% were conductive [5]. Surgical therapies for OME are widely accepted and effective; however, the exact indications for when surgery is needed are somewhat controversial. The most common surgical intervention is myringotomy with tympanostomy tube insertion (TTI). This allows for ventilation of the middle ear reducing fluid accumulation and supporting the eustachian tube, while not directly modifying it [1]. It has long been established that tube placement is better than myringotomy alone in patients with effusion, 2–3 months post operatively [6]. In one meta‐analysis, authors demonstrated that children who received tube insertion had 32% less time with effusion during the first year [7]. Meta‐analysis in adults showed more mixed results with TTI alone, demonstrating that adults who received TTI for OME were more likely to experience persistent secretions [8]. Eustachian tuboplasty (ET) and specifically balloon dilation (BDET) is a relatively new method of treating OME. The procedure was first conducted in 2009 with subsequent studies published in 2010 showing balloon dilation to be a safe and effective procedure [9, 10, 11]. Additional studies on balloon dilation eustachian tuboplasty (BDET) have shown a reduction in symptoms for patients with chronic eustachian tube dysfunction up to 33 months postoperativley [12]. Additional multi center cohort studies showed similar results with improvement in ETDQ‐7 and Valsalva Maneuver at 24‐month follow‐up [13]. Despite success in cohort studies, a meta‐analysis from 2025 showed BDET may show clinically meaningful improvement at up to 3 months. However, past this, there is limited certainty in evidence. The authors of this study argue for more data and long‐term follow‐up [14]. Similarly, ET with radiofrequency ablation (RFA) has been conducted as another treatment for OME. Initial studies showed similar improvement in Valsalva Maneuver and passive tube opening [15]. This was supported in other studies, showing an absence of effusion in a proportion of patients at both the 12‐month and 2‐year mark [16, 17]. In a larger study, patients appeared to have normal aeration of their eustachian tubes at 65.21%, extending to a 3 year period [18]. The objective of this meta‐analysis was to assess if the concurrent and adjunctive treatment of ET, whether balloon dilation or RFA, was superior to TTI alone for otitis media with effusion. Methods PICO The population of interest was patients with COME. The intervention was surgical intervention with co‐occurring ET, either balloon dilation or radiofrequency ablation. The comparison group was tympanostomy tubes alone. The assessed outcomes were eustachian tube dysfunction questionnaire‐7 score (ETDQ‐7), hearing outcomes, recurrence of symptoms or otorrhea, Eustachian Tube Score (ETS) and premature tube extrusion. Literature Search A literature search was performed by two authors independently and in parallel to identify studies that contained both study arms of ET with concurrent TTI and a control group of tympanostomy tubes alone. Reviewers searched PubMed/MEDLINE, Embase, Scopus and Cochrane/CENTRAL using the following Boolean Search criteria: (“Eustachian tube” OR “Eustachian tuboplasty” OR “Eustachian tube balloon dilation” OR ETBD OR “balloon dilation”) AND (“tympanostomy tube” OR “tympanotomy tube” OR “tympanostomy” OR “ear tube” OR TTI) AND (dilat* OR dilation OR tuboplasty) AND (“otitis media” OR “eustachian tube dysfunction” OR OME OR “middle ear effusion” OR “chronic otitis media”) to develop a list of potential studies. After searching the databases, duplicates were removed and titles, abstracts and subsequently manuscripts were reviewed to determine eligibility. Inclusion criteria for eligible studies included studies that compared TTI and concurrent ET, being cohort based, including prospective and retrospective studies, and including measurable outcomes. Ineligible studies were based on the exclusion criteria of containing only one treatment arm (i.e., only ET, only TTI, or co‐occurring ET and TTI but without a control group of TTI alone), studies that were not in English and studies that had incomplete results or were retracted. Additionally, eligible studies and their references were reviewed in parallel to ensure no studies had been missed. Any discrepancies between independent reviewers on eligibility were resolved through discussion. Data Extraction Data from included studies were extracted by two independent reviewers. Patient demographics were assessed for each study and results were compared. Outcome data such as recurrence risk, ETDQ‐7, hearing outcomes, ETS, and tube retention were independently extracted from each study when present and compared between reviewers to ensure accuracy. If certain demographic factors were not directly present in the studies, for example, if the interventions were performed on unilateral or bilateral ears, reviewers attempted to back‐calculate these demographics from the number of ears and patient data that was reported. If reviewers were unable to calculate certain demographic factors or pool data across studies, that outcome was not included in subsequent analysis. Finally, a quality assessment was performed for each study using the Quality Assessment Tool for Observational Cohort and Cross‐Sectional Studies from the National Heart, Lung, and Blood Institute (Figure S1) [19]. Quality assessment was performed by two authors independently and in parallel and any disagreement in a certain criterion was resolved through discussion. Final quality rating was then determined by each author and listed for each study, and a percent agreement was reported. Meta‐Analysis and Narrative Synthesis Each study was assessed to see if outcome data could be pooled across eligible studies. When multiple studies reported on similar outcomes, those results were pooled together using the statistical software MetricGate. For continuous outcomes, including the ETDQ‐7 and ABG reduction, the mean change was calculated as the difference of preoperative from postoperative results for each study. Pooled mean difference was then assessed using a random‐effects model to account for heterogeneity between the studies and was calculated using the pooled mean change scores between the ET + TTI and TTI group across the studies that reported it. This was reported along with a 95% confidence interval and a p‐value, with < 0.05 being considered significant. Inter‐study heterogeneity (I 2) was also quantified and interpreted. Additional outlier analysis was also conducted to further assess heterogeneity. Binary outcomes such as symptoms recurrence/recurrence rate were assessed through pooled risk reduction with 95% confidence intervals. Outcome data that could not be pooled across multiple studies was reported as narrative synthesis in the discussion section. The review and results sections were created following the Preferred Reporting Items for Systemic Reviews and Meta‐Analyses (PRISMA) guidelines [20]. Additionally, a PRISMA check list was completed (Figure S2) [20]. Results Initial literature search generated 191 study abstracts, 37 from PubMed/MEDLINE, 93 from Embase, 50 from Scopus and 11 from Cochrane/CENTRAL; after screening for duplicates, 97 abstracts were left for additional review (Figure 1). Titles were screened based on relevance to the study and were removed if they did not mention both TTI and ET in some variation based on the above Boolean search criteria. Seventy nine studies abstracts were removed based on title, leaving 18 studies abstracts. These abstracts were then screened. Eight were removed from the list of eligible studies; two were screened out based on scope, one was only a proposal with no data, one was not accessible, two were not in English and two were retracted articles. This left 10 studies, which were screened based on review of the full manuscripts. Of those, four were screened out due to lacking a control group of TTI alone, one was only a proposal without data and one only had myringotomy with no tube insertion, leaving four for subsequent analysis (Figure 1). Of the four included in review, all were deemed to have “good” quality (Figure S1). PRISMA flow diagram n = number of studies. Of the included studies, three were prospective cohort studies and one was a retrospective cohort study. A total of 294 ears were included across all four studies (Figure 2). Individual study data with the measured outcomes is shown for each study (Figure 2). All studies looked at ET with TTI (ET + TTI) compared to TTI alone. ET was completed by BDET in three studies, and RFA in the remaining. In patients receiving TTI alone, all studies used local anesthesia with placement of the tympanostomy tubes in the anteroinferior quadrant of the tympanic membrane. In individuals receiving both BDET and TTI, BDET was completed using endoscopic assistance to assess the posterior nasopharynx and the eustachian tube. Then, using a guiding catheter with the balloon apparatus, the balloon was placed into the eustachian tube nasopharyngeal orifice until approximately 20 mm in length had been reached and the device was then inflated to 10 bars for 2 min before being deflated and retracted to achieve tubal dilation. Studies then reported similar surgical methods of completing the TTI as the control group [21, 22, 23]. In the study using RFA + TTI, the RFA portion was completed using an Evac 70 plasma wand, which was set to a power of seven and a coagulation setting of three. RFA was performed at the superior and posterior wall of the eustachian tube orifice. Then, TTI was performed similarly in both the control group and the group with RFA + TTI and as compared to the other studies [24]. Postirradiation eustachian tube dysfunction patients were included in one study; this group had BDET + TTI and TTI alone [21]. The remaining three studies reported data on COME [22, 23, 24]. Characteristics of included studies ET + TTI = Eustachian Tuboplasty + Tympanostomy Tube Insertion TTI = Tympanostomy Tube Insertion ETDQ‐7 = Eustachian Tube Dysfunction Questionnaire SD = standard deviation dB = decibels of sound n (%) = number of patients (rate of recurrence) ETS = Eustachian Tube Score. Meta‐Analysis Demographics were pooled for each study. In the ET + TTI group 141 ears were assessed, with an average age of 42.7 ± 11.3 years, with 54 ears being operated on bilaterally and 33 ears operated on unilaterally. In the TTI control group, 153 ears were assessed with an average age of 45.8 ± 10.4 years, with 56 ears being operated on bilaterally and 41 ears operated on unilaterally (Table 1). TABLE 1Pooled general demographics.ET + TTI (n = 141 ears)TTI (n = 153 ears)Age (year, mean ± SD)42.7 ± 11.345.8 ± 10.4Ear Sides (bilateral/unilateral)54/3356/41Abbreviations: ET + TTI, Eustachian Tuboplasty + Tympanostomy Tube Insertion; TTI, Tympanostomy Tube Insertion. Pooled general demographics. Abbreviations: ET + TTI, Eustachian Tuboplasty + Tympanostomy Tube Insertion; TTI, Tympanostomy Tube Insertion. Meta‐analysis was conducted on poolable data, when multiple studies reported on the same outcome. The first poolable outcome was the ETDQ‐7 questionnaire score, which was assessed using mean change from pre and postoperative, taken at 6 months postop, questionnaire scores presented individually in the Ai M, et al., Wu M., et al., and Fang C et al. papers [21, 23, 24]. Pooled mean difference between the ET + TTI and TTI groups for the ETDQ‐7 questionnaire was calculated as −5.17 (−8.89 to −1.46), with a p‐value of 0.006 and a heterogeneity of 95.10% (Table 2, Figure 3). TABLE 2Pooled mean difference of ETDQ‐7 Questionnaire score between ET + TTI and TTI alone groups from the change in mean preoperatively compared to postoperatively.StudiesMean difference (95% CI) p Heterogeneity (I 2)Ai M. et al. [21]−5.17 (−8.89 to −1.46)0.006*95.1%Wu M. et al. [23]Fang C. et al. [24]Abbreviations: ET + TTI, Eustachian Tuboplasty + Tympanostomy Tube Insertion; ETDQ‐7, Eustachian Tube Dysfunction Questionnaire; TTI, Tympanostomy Tube Insertion, *, significant at a p‐value < 0.05. Pooled mean difference of ETDQ‐7 Questionnaire score between ET + TTI and TTI alone groups from the change in mean preoperatively compared to postoperatively. Abbreviations: ET + TTI, Eustachian Tuboplasty + Tympanostomy Tube Insertion; ETDQ‐7, Eustachian Tube Dysfunction Questionnaire; TTI, Tympanostomy Tube Insertion, *, significant at a p‐value < 0.05. Random‐effects model forest plot of pooled mean difference of ETDQ‐7 questionnaire score between the ET + TTI and TTI groups including all poolable studies. Additional outlier analysis was conducted by removing the Ai M et al. paper which had a significantly lower starting ETDQ‐7 score preoperatively [21]. When this was done the pooled mean difference using only the Wu M. et al. and Fang C et al. papers was calculated as −6.98 (−8.82 to −5.14), with a p‐value < 0.001 and a heterogeneity of 69.00% (Table 3, Figure 4) [ 23, 24]. TABLE 3Outlier analysis of pooled mean difference of ETDQ‐7 Questionnaire score between ET + TTI and TTI alone groups from the change in mean preoperatively compared to postoperatively without outlier study.StudiesMean difference (95% CI) p Heterogeneity (I 2 ) Wu M. et al. [23], Fang C. et al. [24], −6.98 (−8.82 to −5.14)< 0.001*69.00%Abbreviations: ET + TTI, Eustachian Tuboplasty + Tympanostomy Tube Insertion; ETDQ‐7, Eustachian Tube Dysfunction Questionnaire; TTI, Tympanostomy Tube Insertion, *, significant at a p‐value < 0.05. Outlier analysis of pooled mean difference of ETDQ‐7 Questionnaire score between ET + TTI and TTI alone groups from the change in mean preoperatively compared to postoperatively without outlier study. Wu M. et al. [23], Fang C. et al. [24], Abbreviations: ET + TTI, Eustachian Tuboplasty + Tympanostomy Tube Insertion; ETDQ‐7, Eustachian Tube Dysfunction Questionnaire; TTI, Tympanostomy Tube Insertion, *, significant at a p‐value < 0.05. Outlier analysis displaying a random‐effects model forest plot of pooled mean difference of ETDQ‐7 questionnaire score between the ET + TTI and TTI groups. Additionally, Air‐Bone‐Gap Reduction between pre and postoperative audiograms was assessed. Individual ABG reduction was presented in Ai M et al., Wu M. et al., and Fang C et al. papers [21, 23, 24]. Pooled mean difference between the ET + TTI and TTI group for ABG Reduction was calculated as 5.93 (0.25–11.84) with a p‐value of 0.049 and a heterogeneity of 95.30% (Table 4, Figure 5). TABLE 4Pooled air‐bone‐gap reduction between pre and postoperative audiograms.StudiesABG reduction (dB) (95% CI) p Heterogeneity (I 2 ) Ai M. et al. [21], Wu M. et al. [23], Fang C. et al. [24], 5.93 (0.025–11.84)0.049*95.30%Abbreviations: dB, decibels of sound; ET + TTI, Eustachian Tuboplasty + Tympanostomy Tube Insertion; TTI, Tympanostomy Tube Insertion, *, significant at a p‐value < 0.05. Pooled air‐bone‐gap reduction between pre and postoperative audiograms. Ai M. et al. [21], Wu M. et al. [23], Fang C. et al. [24], Abbreviations: dB, decibels of sound; ET + TTI, Eustachian Tuboplasty + Tympanostomy Tube Insertion; TTI, Tympanostomy Tube Insertion, *, significant at a p‐value < 0.05. Random‐effects model forest plot of pooled mean difference of Air‐Bone‐Gap reduction between the ET + TTI and TTI groups including all poolable studies. Additional outlier analysis was conducted again by removing the Ai M et al. paper [21]. When this was done, the pooled mean difference using only the Wu M. et al. and Fang C et al. papers was calculated as 3.40 (−2.35 to 9.16), with a p‐value of 0.25 and a heterogeneity of 94.30 (Table 5, Figure 6) [ 23, 24]. TABLE 5Outlier‐analysis of pooled air‐bone‐gap reduction between pre and postoperative audiograms.StudiesABG reduction (dB) (95% CI) p Heterogeneity (I 2 ) Wu M. et al. [23], Fang C. et al. [24], 3.40 (−2.35 to 9.16)0.2594.30%Abbreviations: dB, decibels of sound; ET + TTI, Eustachian Tuboplasty + Tympanostomy Tube Insertion; TTI, Tympanostomy Tube Insertion. Outlier‐analysis of pooled air‐bone‐gap reduction between pre and postoperative audiograms. Wu M. et al. [23], Fang C. et al. [24], Abbreviations: dB, decibels of sound; ET + TTI, Eustachian Tuboplasty + Tympanostomy Tube Insertion; TTI, Tympanostomy Tube Insertion. Outlier analysis displaying a random‐effects model forest plot of pooled mean difference of Air‐Bone‐Gap reduction between the ET + TTI and TTI groups. Figure S1 Study quality rating table Figure S2 PRISMA check list. Additionally, pooled recurrence of symptoms was assessed, which was primarily described as persistence of secretions or otorrhea despite intervention. This was presented individually in the Ai M et al., Li YQ et al., and Fang C et al. papers [21, 22, 24]. Pooled average recurrence rates for the ET + TTI group were calculated as three patients with an average recurrence rate of 9.9%, compared to the TTI group, where it was present in an average of nine patients with an average recurrence rate of 24.9% (p = 0.02) (Table 6). Further calculations on risk reduction were completed based on total number of recurrences across the three studies that reported it. ET + TTI reduced recurrence events from 24.3% to 8.4%, corresponding to an absolute risk reduction of 15.9%, with a relative risk of 0.35 (95% CI: 0.17–0.70) and a relative risk reduction of 65.4% (95% CI: 30%–83%) (Table 6). TABLE 6Pooled relative risk of recurrence of symptoms.ET + TTI, n (%)TTI, n (%) p RR (95% CI)Heterogeneity (I 2 )Recurrence of Symptoms3 (9.9%)9 (24.9%)0.020.35 (0.17–0.70)61%Abbreviations: ET + TTI, Eustachian Tuboplasty + Tympanostomy Tube Insertion; n (%), number of patients (rate of recurrence); RR, risk reduction; TTI, Tympanostomy Tube Insertion. Pooled relative risk of recurrence of symptoms. Abbreviations: ET + TTI, Eustachian Tuboplasty + Tympanostomy Tube Insertion; n (%), number of patients (rate of recurrence); RR, risk reduction; TTI, Tympanostomy Tube Insertion. Additional outcomes, such as ETS (score ± SD) and tube extrusion (n, %) were only presented in one of the four studies, one in Ai M. et al. and one in Fang C. et al. thus they were not included in meta‐analysis but are accounted for as individual data and subsequent narrative synthesis (Figure 2) [21, 24]. Discussion The primary factor creating OME has been proposed to be physiological dysfunction of the eustachian tube, which creates inadequate drainage of the middle ear, leading to effusion [1]. This dysfunction, whether it be from mucosal swelling, postirradiation fibrosis, or extrinsic obstruction, still creates eustachian tube dysfunction and OME [1, 3]. Surgical management has long been considered to be an effective option for this, and meta‐analyses have demonstrated that TTIs are effective [8]. However, their effectiveness may be more limited in the adult population, and adults are less likely to have improved hearing and are more likely to experience persistent otorrhea after TTI insertion [8]. In other meta‐analyses looking at BDET and RFA, both were shown to be effective for eustachian tube dysfunction [14, 18]. But these studies were limited in that they did not necessarily focus on patients with OME and instead focused on adults with obstructive eustachian tube dysfunction. The exact rates of OME were not assessed and instead were simply included as a possible manifestation of the broader umbrella term of eustachian tube dysfunction. Several single‐arm studies, lacking a control group, have been performed showing a benefit with concurrent ET + TTI. One study from 2024 showed that concurrent BDET and TTI demonstrated a long‐term success in 34 out of 36 ears (94.4%) at reducing symptoms, with all postoperative tympanograms and audiograms being 100% normal 12 months after the procedure [25]. Similarly, a study in 2019 showed concurrent BDET and TTI insertion in 62 ears, demonstrating significant improvement (p < 0.05) in both ETS and (Eustachian tube dysfunction questionnaire‐7) ETDQ‐7 scores up to 12 months postoperatively. Concluding that treatments together do result in significant subjective and objective improvements [26]. The same has been demonstrated with RFA tuboplasty in patients with COME who had previously demonstrated premature TT extrusion. A study from 2024 showed when both modalities (RFA + TTI) were performed, tube retention was shown in 21 out of 23 patients (91.3%). None of the patients had serious adverse events, leading the authors to conclude that combining the modalities may serve as an effective technique [27]. The problem with the aforementioned studies is that none of them compared the adjunctive ET + TTI to TTI alone making the generalizability of their conclusions limited. What we found to be lacking in the existing literature were studies specifically assessing if combined surgical treatments (TTI + ET) were superior to TTI alone. Additionally, we found no existing systematic review assessing combined treatments. The goal with this systematic review was to use existing studies that contained a control group and pool data across the studies to see if there was a significant difference in using ET as an adjunctive therapy with TTI when compared to TTI alone. Due to limited existing studies, we accepted a certain degree of heterogeneity in our pooled results. First, we included studies that had ETBD and RFA, as both are accepted modalities for ET. Additionally, one of the studies was chronic otitis media from postirradiation, which we acknowledge to be a different mechanism of pathogenesis from standard COME. However, despite differing etiologies, clinical treatment remains the same, mostly focused on TTI, which is why it was appropriate to include it in our analysis [28, 29]. Postirradiation OME typically occurs after the treatment of nasopharyngeal carcinoma. The pathogenesis of this dysfunction primarily involves eustachian tube dysfunction and obstruction resulting in increased middle ear negative pressure and thus fluid accumulation, leading to a similar clinical burden as allergic otitis media with effusion. This is due to multiple factors like radiation‐induced injury and local immune responses that may have varying degrees of responsibility and usually act together to create dysfunction [30]. The proposed principal etiological factor is radiation‐induced injury [30]. In a meta‐analysis focused specifically on postirradiation otitis media with effusion, one of the only studies to demonstrate prolonged effectiveness in treatment for postirradiation eustachian tube dysfunction was the Ai M. et al. study [21] which included both BDET + TTI and had effectiveness rates of 93.75%, which was higher than other studies included in the meta‐analysis that used TTI or BDET separately [30]. Among the included studies, there were no major demographic differences between the ET + TTI and TTI groups and the number of ears included was comparable across cohorts. For ETDQ‐7 score, pooled analysis demonstrated significant improvement favoring the ET + TTI group with a mean difference of −5.17 (95% CI: −8.89 to −1.46, p = 0.006) (Table 2, Figure 3). However, heterogeneity was considerable (I 2 = 95.10%). Given the limited number of available studies and clinical variability among cohorts, outlier analysis was performed by excluding the Ai M et al. paper, which evaluated postirradiation otitis media with effusion and had a substantially lower baseline ETDQ‐7 scores compared with the other included studies with an average score at 8.61 between the ET + TTI and TTI group [21]. Following exclusion heterogeneity was reduced to 69.00% (Table 3), while the pooled mean difference increased to −6.98 (−8.82 to −5.15) (Table 3, Figure 4). These findings suggest that patients with postirradiation OME have differing subjective symptoms when compared to patients with traditional COME and thus varying improvement when assessing ET + TTI and the TTI group. With lower baseline subjective symptom severity on the ETDQ‐7, symptom improvement with ET + TTI is more modest; however, additional data is necessary to fully evaluate this relationship. Air‐Bone‐Gap Reduction was assessed similarly. Pooled analysis demonstrated some improvement and a milder favoring of the ET + TTI group with a mean difference of 5.93 dB (95% CI: 0.025–11.84 dB, p = 0.049). Again, heterogeneity was considerable (I 2 = 95.30) (Table 4, Figure 5). Outlier analysis was again conducted by removing the Ai M et al. paper which resulted in a very minimal reduction in heterogeneity (I 2 = 94.30%) (Table 5, Figure 6). Compared to the ETDQ‐7 score this improvement was more limited. This may suggest that ET + TTI has more effect in improving subjective symptomatology rather than objective audiological assessment. However, additional studies and data need to be reported to fully evaluate this relationship. The number of symptom recurrence and the rate of recurrence demonstrated a significant reduction favoring the ET + TTI group, with a pooled relative risk of 0.35% (95% CI: 0.17–0.70, p = 0.02). This demonstrated a moderate to substantial heterogeneity (I 2 = 61%). The ET + TTI group did demonstrate a significantly lower rate of symptom recurrence suggesting that this methodology may provide a more substantial clinical benefit to patients with OME and could potentially be a better clinical option at providing longer and more sustainable treatment, thus reducing the burden of cost and time for both patients and physicians. Secondary outcomes that were unable to be pooled due to limitations in study presentations were ETS and tube extrusion rates (Figure 2). Li YQ et al. reported ETS scoring, which, like the ETDQ‐7, is a partially subjective measure but also has an objective component. It is scored on a 0–2‐point system, where 0 represents more symptoms and 2 represents fewer symptoms; this aspect is subjective in that patients rate perceived symptoms of fullness, noise during swallowing or Valsalva, and hearing loss. An objective measure is used for change in pressure during tympanometry, where 0 is no change, 1 is a change between 5–10 daPa, and 2 is a change over 10 daPa. In this study, ET + TTI patients demonstrated a preoperative ETS (score ± SD) of 2.34 ± 0.97 and in the TTI group 2.20 ± 0.40. Postoperatively at 6 months, the ET + TTI patients demonstrated a preoperative ETS (score ± SD) of 7.86 ± 0.90 compared to the TTI group at 5.49 ± 0.90 [22]. Additionally, the Fang C. et al. paper showed a tube extrusion rate n (%) of 2 (4.7%) for the ET + TTI group and 9 (21.4%) for the TTI group [24]. Both of these data points are from individual studies and thus we can only report them as narrative synthesis, making their generalizability limited. However, despite this, there is still demonstrated clinical outcome favorability for ET + TTI when compared to TTI alone. Another primary limitation of this systematic review is that there is a limited number of studies that exist with adequate control groups. This limits the generalizability of our results due to limited power. Additionally, studies primarily reported their outcomes and comparisons at the ear level rather than a patient level. This may contribute to ear‐level clustering as reported. Since patient level data were not consistently reported, formal analysis on how this clustering impacted data analysis was not feasible. Considerable heterogeneity is also present with the included studies including differing etiology of disease and baseline symptom severity. This is likely what contributed to such high heterogeneity within the data analysis and additional studies should be completed and added to this analysis to fully understand how this impacts data heterogeneity. Based on these limitations, interpretation should be continued and additional studies with adequate control groups need to be conducted to be able to confidently state that concurrent ET with TTI is better than TTI alone. What this analysis does suggest is that ET + TTI was associated with improved outcomes such as subjective symptom scoring on the ETDQ‐7 and a reduction in symptom recurrence. Conclusion Based on the results of this systematic review and meta‐analysis, ET + TTI demonstrated a statistically significant reduction in the rates of otorrhea and symptom recurrence for OME in adults when compared to TTI alone. Additionally, ET + TTI demonstrated favorable pooled outcomes compared to TTI alone. The primary limitation of the systematic review is the number of studies that met inclusion criteria. There is a need for additional prospective cohort studies to be conducted to definitively determine that using ET as an adjunctive treatment with TTI is superior to TTI alone for COME in adults. Funding The authors have nothing to report. Disclosure All intellectual content and critical revisions were made by the authors without the use of generative AI. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: Quality rating table. Figure S2: PRISMA check list. Acknowledgments The authors have nothing to report. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Figure S1: Quality rating table. Figure S2: PRISMA check list. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.